MedTrace Logo

Metagenomic Analysis of Human Gut Microbiota in Patients With Metabolic Diseases Including Diabetes

NCT03204799 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2019-01-10

No results posted yet for this study

Summary

Microbiota is important for immunology, hormonal and metabolic homeostasis in human and could influence on developing diabetes and obesity. Recent studies investigates microbiota by metagenomic sequencing, however, the composite of microbiota and its metabolic role has not been fully determined. Metagenomics and microbiome analysis could early diagnose metabolic disorders and suggest treatment options for metabolic diseases.

In this study, the investigators investigate the composite of microbiota and deduct basic information for treatment models using metagenomic sequencing.

Conditions

Interventions

OTHER

Metformin

newly diagnosed type 2 diabetes patients who start to metformin monotherapy

DRUG

SGLT2 inhibitor

newly diagnosed type 2 diabetes patients who start to SGLT2 inhibitor monotherapy

DRUG

ezetimibe

newly diagnosed dyslipidemia patients who start to ezetimibe therapy

Sponsors & Collaborators

  • Yonsei University

    lead OTHER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-12-17
Primary Completion
2019-09-30
Completion
2019-12-16

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03204799 on ClinicalTrials.gov